We are seeking a Director of Mass Spectrometry, R&D to serve as technology and analytics lead. This role supports Clinical Chemistry R&D efforts, drives the proteomic and metabolomic discovery and assay development pipelines, conducts research to accelerate biomarker discovery for use in the clinic and to scale-up methods for production.
Responsibilities:
- Lead the development, validation and performance of biomarker discovery methods and analysis to support clinical assays.
- Lead development of data analysis workflows and software to perform quantitative measurements of multiple analytes using liquid chromatography mass spectrometry (LC-MS).
- Supervise validation activities and technology transfer to the laboratory operations.
- Supervise LC-MS proteomic and metabolomic product and services launches.
- Supervise analytics team to ensure compatibility and integration with the middleware, providing automated result reporting to the diagnostic LIS
- Hire and train scientists and analysis teams.
- Provide necessary support to QA and RA to ensure compliance with regulations.
Education/Experience Required:
- MS or Ph.D. in Chemistry or Computer Sciences
- 5+ years of experience with data analysis for Mass Spectrometry, performing quantitative analysis of common metabolites
- Strong background in mathematics and physics
- Fluency in programming languages
- Experience with other analytical techniques is highly desirable.
- Familiarity with Thermo Fisher Scientific and Agilent MS systems is a plus.
- Excellent written and oral communication skills.
- Strong interpersonal skills with a track record of collaboration and teamwork.
- Self-starting ability with exceptional time and project management skills.
About Us
Co-founded by CEO Fred Turner and powered by a team of world-leading doctors, scientists, engineers, and health industry experts, Curative responded in March 2020 to the urgent need for COVID-19 testing, ultimately developing a network of thousands of testing sites across over 40 states and three CLIA-certified, high-complexity laboratories. As a result, Curative and its managed medical entities provided over 30 million COVID-19 tests and over 2 million COVID-19 vaccines.
Curative’s patient-facing services, healthcare facilities, integrated supply chain, and labs are part of a large platform we've built from the ground up that has allowed us to grow quickly and more efficiently than other healthcare companies. As a result, we were one of the first companies to respond to the pandemic providing COVID-19 testing at scale across the United States.
We are now implementing a new model of comprehensive healthcare delivery focused on the whole person's well-being: providing expanded healthcare and wellness services while also streamlining access to preventative care. We are setting out to change healthcare in the United States and fundamentally re-designing the way that patients interact with their healthcare and health insurance. By building a connected platform for managing the health of our patients, we believe that we can deliver a better healthcare experience at a lower cost and with better outcomes so that our patients can focus on getting and staying well. Our model delivers healthcare by investing in patient preventive health from the start, reducing the barriers to entry to traditionally complex care networks and eliminating the concern of unexpected medical bills. Curative will launch its first members-only healthcare offering in Austin, January 2023.
For more details on Curative and to stay tuned on what’s ahead, please visit curative.com and follow on Facebook, Instagram, and Twitter.